Is Dr. Lal PathLabs (NSE:LALPATHLAB) Using Too Much Debt?

Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know worries about.' When we think about how risky a company is, we always like to look at its use of debt, since debt overload can lead to ruin. Importantly, Dr. Lal PathLabs Limited (NSE:LALPATHLAB) does carry debt. But is this debt a concern to shareholders?

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Why Does Debt Bring Risk?

Generally speaking, debt only becomes a real problem when a company can't easily pay it off, either by raising capital or with its own cash flow. Part and parcel of capitalism is the process of 'creative destruction' where failed businesses are mercilessly liquidated by their bankers. However, a more frequent (but still costly) occurrence is where a company must issue shares at bargain-basement prices, permanently diluting shareholders, just to shore up its balance sheet. Of course, plenty of companies use debt to fund growth, without any negative consequences. When we think about a company's use of debt, we first look at cash and debt together.

What Is Dr. Lal PathLabs's Debt?

The image below, which you can click on for greater detail, shows that Dr. Lal PathLabs had debt of ₹1.57b at the end of March 2025, a reduction from ₹2.47b over a year. However, it does have ₹11.6b in cash offsetting this, leading to net cash of ₹10.1b.

How Strong Is Dr. Lal PathLabs' Balance Sheet?

Zooming in on the latest balance sheet data, we can see that Dr. Lal PathLabs had liabilities of ₹4.02b due within 12 months and liabilities of ₹1.08b due beyond that. On the other hand, it had cash of ₹11.6b and ₹1.24b worth of receivables due within a year. So it actually has ₹7.78b more liquid assets than total liabilities.

This short term liquidity is a sign that Dr. Lal PathLabs could probably pay off its debt with ease, as its balance sheet is far from stretched. Simply put, the fact that Dr. Lal PathLabs has more cash than debt is arguably a good indication that it can manage its debt safely.

See our latest analysis for Dr. Lal PathLabs

And we also note warmly that Dr. Lal PathLabs grew its EBIT by 18% last year, making its debt load easier to handle. The balance sheet is clearly the area to focus on when you are analysing debt. But it is future earnings, more than anything, that will determine Dr. Lal PathLabs's ability to maintain a healthy balance sheet going forward. So if you're focused on the future you can check out this free report showing analyst profit forecasts.

But our final consideration is also important, because a company cannot pay debt with paper profits; it needs cold hard cash. Dr. Lal PathLabs may have net cash on the balance sheet, but it is still interesting to look at how well the business converts its earnings before interest and tax (EBIT) to free cash flow, because that will influence both its need for, and its capacity to manage debt. Happily for any shareholders, Dr. Lal PathLabs actually produced more free cash flow than EBIT over the last three years. That sort of strong cash generation warms our hearts like a puppy in a bumblebee suit.

Summing Up

While it is always sensible to investigate a company's debt, in this case Dr. Lal PathLabs has ₹10.1b in net cash and a decent-looking balance sheet. The cherry on top was that in converted 100% of that EBIT to free cash flow, bringing in ₹5.2b. So is Dr. Lal PathLabs's debt a risk? It doesn't seem so to us. There's no doubt that we learn most about debt from the balance sheet. But ultimately, every company can contain risks that exist outside of the balance sheet. We've identified 1 warning sign with Dr. Lal PathLabs , and understanding them should be part of your investment process.

At the end of the day, it's often better to focus on companies that are free from net debt. You can access our special list of such companies (all with a track record of profit growth). It's free.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.